Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift https://www.drugdiscoverytrends.com...r-a-therapy-that-could-fill-a-clinical-shift/ DT120’s commercial upside could be enormous if one or a few doses deliver multi-month benefit, because that would make a 5–8 hour monitored session economically compelling even at premium pricing.
